What is HC Wainwright's Forecast for RARE FY2026 Earnings?

Key Points

• HC Wainwright forecasts a FY2026 loss of $1.51 per share for Ultragenyx, narrower than the cited consensus estimate of a $3.21-per-share loss. The firm maintains a Buy rating and a $25 price target.
• HC Wainwright also estimates FY2027 earnings of $6.38 per share, including positive quarterly EPS forecasts throughout that year.
• Ultragenyx’s latest quarter missed estimates, reporting a $1.16-per-share loss versus $1.10 expected and revenue of $173 million versus $182.49 million expected; revenue nevertheless grew 8.2% year over year.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Research analysts at HC Wainwright issued their FY2026 earnings estimates for shares of Ultragenyx Pharmaceutical in a note issued to investors on Thursday, November 5th. HC Wainwright analyst R. Selvaraju anticipates that the biopharmaceutical company will earn ($1.51) per share for the year. HC Wainwright currently has a "Buy" rating and a $25.00 target price on the stock. The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($3.21) per share. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical's Q4 2026 earnings at $2.35 EPS, Q1 2027 earnings at $0.63 EPS, Q2 2027 earnings at $1.38 EPS, Q3 2027 earnings at $1.73 EPS, Q4 2027 earnings at $2.64 EPS and FY2027 earnings at $6.38 EPS.

Several other brokerages have also weighed in on RARE. William Blair upgraded Ultragenyx Pharmaceutical to a "hold" rating in a report on Wednesday, September 23rd. Wedbush dropped their price target on shares of Ultragenyx Pharmaceutical from $25.00 to $22.00 and set a "neutral" rating on the stock in a research report on Wednesday, November 4th. Royal Bank Of Canada downgraded shares of Ultragenyx Pharmaceutical from a "moderate buy" rating to a "hold" rating in a report on Thursday, September 3rd. Weiss Ratings restated a "sell (d-)" rating on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, October 6th. Finally, Citigroup reduced their price objective on shares of Ultragenyx Pharmaceutical from $32.00 to $22.00 and set a "buy" rating for the company in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $29.79.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE stock opened at $15.43 on Monday. Ultragenyx Pharmaceutical has a 1 year low of $12.73 and a 1 year high of $39.89. The stock has a market cap of $1.57 billion, a PE ratio of -2.97 and a beta of 0.37. The business's fifty day moving average is $16.02 and its 200-day moving average is $22.71.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing analysts' consensus estimates of ($1.10) by ($0.06). The company had revenue of $173.00 million for the quarter, compared to analyst estimates of $182.49 million. During the same quarter in the previous year, the company earned ($1.81) EPS. Ultragenyx Pharmaceutical's revenue for the quarter was up 8.2% on a year-over-year basis.

Institutional Trading of Ultragenyx Pharmaceutical

Hedge funds have recently made changes to their positions in the stock. Allworth Financial LP lifted its stake in shares of Ultragenyx Pharmaceutical by 18.9% in the 3rd quarter. Allworth Financial LP now owns 5,588 shares of the biopharmaceutical company's stock valued at $84,000 after purchasing an additional 889 shares during the last quarter. Versant Capital Management Inc increased its position in Ultragenyx Pharmaceutical by 662.9% during the second quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company's stock worth $38,000 after buying an additional 1,001 shares during the last quarter. GAMMA Investing LLC increased its position in Ultragenyx Pharmaceutical by 149.5% during the second quarter. GAMMA Investing LLC now owns 1,919 shares of the biopharmaceutical company's stock worth $64,000 after buying an additional 1,150 shares during the last quarter. Sterling Capital Management LLC increased its position in Ultragenyx Pharmaceutical by 102.4% during the third quarter. Sterling Capital Management LLC now owns 2,475 shares of the biopharmaceutical company's stock worth $37,000 after buying an additional 1,252 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in Ultragenyx Pharmaceutical during the second quarter valued at about $48,000. 97.67% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,066 shares of the business's stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $15.27, for a total transaction of $107,897.82. Following the sale, the chief financial officer directly owned 89,229 shares of the company's stock, valued at $1,362,526.83. The trade was a 7.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 8,510 shares of company stock worth $127,561. 5.20% of the stock is owned by insiders.

Ultragenyx Pharmaceutical News Summary

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: The UK medicines regulator has accepted Ultragenyx’s marketing application for rebi-vec (UX111), its gene therapy for Sanfilippo syndrome Type A, and is reviewing it. This is a step toward a possible UK authorization, but the therapy remains investigational and has not been approved. Company announcement
• Positive Sentiment: H.C. Wainwright and TD Cowen both reiterated Buy ratings, signaling that these analysts see potential despite recent price-target reductions. H.C. Wainwright rating TD Cowen rating
• Negative Sentiment: Several firms have lowered their price targets, reflecting more restrained expectations. Canaccord cut its target from $39 to $34, Citi reduced its target from $32 to $22, and Barclays lowered its target from $35 to $32; all retained Buy or Overweight ratings. The revisions may weigh on sentiment even as analysts remain positive on the shares. Canaccord target revision Citi target revision

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company concentrates on conditions with significant unmet medical needs, including genetic, metabolic and endocrine disorders, and uses biologics, small molecules and gene therapy approaches in its research and development programs.

Ultragenyx's commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), a therapy for long-chain fatty acid oxidation disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.